NEOMEDLIGHT

Their core work

NEOMEDLIGHT is a French medical device SME specializing in photobiomodulation (PBM) therapy — the use of specific red and near-infrared LED wavelengths to trigger biological healing responses in tissue. Their core application is managing severe complications from cancer treatments such as radiotherapy and chemotherapy, particularly conditions like oral mucositis where patients suffer painful tissue damage. They progressed systematically from a feasibility concept (ONCORED, 2018) to a fully funded development project (CareMin650, 2019–2022), suggesting a focused, product-driven company building toward clinical deployment. Their technology sits at the intersection of oncology supportive care and photonics-based medical devices.

What they specialise in

How they've shifted over time

NEOMEDLIGHT's H2020 participation spans only 2018–2022 with two closely related projects, making it less a story of evolution and more of a single focused trajectory. The 2018 ONCORED project was a short Phase 1 feasibility study (€50k), which validated the concept of red-light photobiomodulation as a medical intervention. By 2019, they had secured Phase 2 funding (€2.4M) under CareMin650, shifting from concept validation to full device development and likely clinical testing. There is no divergence in topic — this is a company with one clear product vision, executing it in stages.

NEOMEDLIGHT is on a product commercialization path — their Phase 2 project ran through 2022, so they are likely now in late-stage clinical validation or early market entry for their red-LED oncology device.

How they like to work

NEOMEDLIGHT has acted exclusively as coordinator across both projects, never joining a consortium as a partner — a profile typical of founder-led SMEs developing a proprietary product rather than offering services to others. Their consortium footprint is minimal: only one unique partner across two projects, all within France, suggesting they keep their R&D tightly controlled. Working with them likely means collaborating on their terms, around their specific device and therapeutic application.

NEOMEDLIGHT has worked with only one consortium partner across its entire H2020 history, entirely within France. Their network is very narrow, likely limited to a single clinical or technical collaborator for device testing or regulatory work.

What sets them apart

NEOMEDLIGHT occupies a specific niche: non-pharmacological, light-based treatment of cancer therapy side effects — a market where few SMEs have secured substantial EU funding. Their successful Phase 1 to Phase 2 progression with the same product concept signals a credible, validated technology rather than early-stage speculation. For consortium builders in oncology, digital health, or medical photonics, they bring proprietary device IP and clinical development experience that is difficult to replicate from a generalist partner.

Highlights from their portfolio

• CareMin650
  The largest project by far at €2.39M, this SME Phase 2 award represents a full development cycle for their red-LED photobiomodulation device targeting severe cancer treatment complications — one of the higher-value single-company SME Instrument grants.
• ONCORED
  A Phase 1 feasibility grant that directly seeded the larger CareMin650 project, demonstrating a textbook EU SME Instrument phase progression from concept to scale.